Isomorphic Labs Secures $5B to Advance AI Drug Discovery

Isomorphic Labs Raises $5 Bn in Series C Funding

Isomorphic Labs Raises $5 Bn in Series C Funding

The London-based AI drug development company will use the proceeds to further develop its drug design engine, IsoDDE, and advance the pipeline of preclinical programs generated through the platform.

Alphabet-backed Isomorphic Labs has raised $5 billion in a Series C funding round, six months after securing $2.1 billion in Series B financing, to advance its AI-powered drug discovery platform and expand its preclinical pipeline and clinical development capabilities.

The London-based AI drug development company will use the proceeds to further develop its drug design engine, IsoDDE, and advance the pipeline of preclinical programs generated through the platform. The funding will also support investments in translational and clinical development infrastructure to prepare programs for human testing.

Founded in 2021 as a spin-off from DeepMind, a Google sibling known for developing AlphaFold, Isomorphic Labs applies artificial intelligence and machine learning to drug discovery and design. In May 2026, the company raised $2.1 billion in a Series B round, followed by the latest $5 billion financing.

Isomorphic's internal pipeline spans multiple drug modalities, with a focus on oncology and immunology. While the company has not disclosed detailed information about its programs, it has reported that IsoDDE outperforms AlphaFold 3 on a protein-ligand structure prediction benchmark and can identify novel binding sites.

In a statement, Isomorphic President Max Jaderberg, Ph.D., said the company’s machine learning researchers and drug hunters “are routinely solving complex biological problems that have stalled traditional research for decades.”

However, the company has yet to disclose detailed preclinical data or demonstrate how drug candidates developed using IsoDDE perform in human trials. It has described its preclinical results as “positive.”

Greenoaks and Sequoia Capital co-led the Series C round, with participation from Andreessen Horowitz and several other new investors. Alphabet also made a significant investment. Existing investors, including Thrive Capital, MGX, GV, CapitalG, Temasek and the U.K. Sovereign AI Fund, also participated.

The latest financing follows a series of partnerships and funding announcements. In 2024, Isomorphic disclosed research collaborations with Eli Lilly and Novartis, with a combined potential value of approximately $3 billion, including milestone payments. The company subsequently raised $600 million in its first external funding round in 2025.

In early 2026, Isomorphic added Johnson & Johnson to its list of research partners through a collaboration focused on drug discovery.

Stay tuned for more such updates on Digital Health News

Follow us

More Articles By This Author


Show All

Welcome back.

Pick up where you left off on Digital Health News.

Sign in to DHN

For existing DHN and DHN Plus members.

or
Continue with Google
New to DHN?